Spero Therapeutics, Inc. 8K

Spero Therapeutics reported Q2 2026 results and announced U.S. FDA approval of Utebzi, an exclusive global (ex‑Greater China) SP001 license, a $105 million royalty financing, and a new Chief Medical Officer, extending its cash runway into 2029.

On August 12, 2026, Spero Therapeutics, Inc. reported its second quarter 2026 results and a broad business update, highlighting FDA approval of Utebzi (tebipenem pivoxil) as the first and only oral carbapenem antibiotic for adult cUTI patients with limited alternatives, an exclusive worldwide (ex-Greater China) license from Innovent Biologics for SP001 (a Phase 2–ready, third‑generation anti‑CD40L antibody) that the company plans to advance into Phase 2 for IgG4‑related disease, and a $105 million non‑recourse, non‑dilutive royalty financing with affiliates of HealthCare Royalty Partners (HCRx) backed by a portion of future GSK‑related Utebzi milestones and royalties, which extends Spero’s cash runway into the second half of 2029; the company also announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer and disclosed a higher quarterly net loss driven by the absence of prior‑year collaboration and grant revenue, alongside reduced R&D expenses following early cessation of the pivotal Phase 3 Utebzi trial for efficacy.

Filing Facts

CIK

1701108

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-346855

Alert Tier

7